282 related articles for article (PubMed ID: 9342580)
21. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
Azizi M; Ménard J; Bissery A; Guyenne TT; Bura-Rivière A; Vaidyanathan S; Camisasca RP
J Am Soc Nephrol; 2004 Dec; 15(12):3126-33. PubMed ID: 15579516
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme inhibitor imidapril with hydrochlorothiazide, bisoprolol and nilvadipine.
Breithaupt-Grögler K; Ungethüm W; Meurer-Witt B; Belz GG
Eur J Clin Pharmacol; 2001 Jul; 57(4):275-84. PubMed ID: 11549204
[TBL] [Abstract][Full Text] [Related]
23. Beta adrenoceptor blockade in rabbit inhibits the renin-releasing effect of AT1 receptor antagonist losartan.
Hajj-Ali AF; Wong PC
J Pharmacol Exp Ther; 1993 Dec; 267(3):1423-7. PubMed ID: 7903389
[TBL] [Abstract][Full Text] [Related]
24. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
He YL; Ligueros-Saylan M; Sunkara G; Sabo R; Zhao C; Wang Y; Campestrini J; Pommier F; Dole K; Marion A; Dole WP; Howard D
J Clin Pharmacol; 2008 Jan; 48(1):85-95. PubMed ID: 17986525
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic interactions of valsartan and hydrochlorothiazide: an open-label, randomized, 4-period crossover study in healthy Egyptian male volunteers.
Hedaya MA; Helmy SA
Clin Ther; 2013 Jun; 35(6):846-61. PubMed ID: 23795576
[TBL] [Abstract][Full Text] [Related]
26. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
Azizi M; Chatellier G; Guyene TT; Murieta-Geoffroy D; Ménard J
Circulation; 1995 Aug; 92(4):825-34. PubMed ID: 7641363
[TBL] [Abstract][Full Text] [Related]
27. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals.
Azizi M; Ménard J; Bissery A; Guyene TT; Bura-Rivière A
Clin J Am Soc Nephrol; 2007 Sep; 2(5):947-55. PubMed ID: 17702736
[TBL] [Abstract][Full Text] [Related]
28. The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects.
Kovarik JM; Lu M; Riviere GJ; Barbet I; Maton S; Goldwater DR; Schmouder RL
Eur J Clin Pharmacol; 2008 May; 64(5):457-63. PubMed ID: 18196225
[TBL] [Abstract][Full Text] [Related]
29. Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake.
Jones MR; Sealey JE; Laragh JH
Am J Hypertens; 2007 Aug; 20(8):907-16. PubMed ID: 17679042
[TBL] [Abstract][Full Text] [Related]
30. A Single-Center, Open-Label, 3-Way Crossover Trial to Determine the Pharmacokinetic and Pharmacodynamic Interaction Between Nebivolol and Valsartan in Healthy Volunteers at Steady State.
Chen CL; Desai-Krieger D; Ortiz S; Kerolous M; Wright HM; Ghahramani P
Am J Ther; 2015; 22(5):e130-40. PubMed ID: 25853236
[TBL] [Abstract][Full Text] [Related]
31. Effect of angiotensin II on pulse wave velocity in humans is mediated through angiotensin II type 1 (AT(1)) receptors.
Rehman A; Rahman AR; Rasool AH
J Hum Hypertens; 2002 Apr; 16(4):261-6. PubMed ID: 11967720
[TBL] [Abstract][Full Text] [Related]
32. Valsartan/hydrochlorothiazide.
Langtry HD; McClellan KJ
Drugs; 1999 May; 57(5):751-5; discussion 756-8. PubMed ID: 10353300
[TBL] [Abstract][Full Text] [Related]
33. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man.
Flesch G; Müller P; Lloyd P
Eur J Clin Pharmacol; 1997; 52(2):115-20. PubMed ID: 9174680
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.
Criscione L; de Gasparo M; Bühlmayer P; Whitebread S; Ramjoué HP; Wood J
Br J Pharmacol; 1993 Oct; 110(2):761-71. PubMed ID: 8242249
[TBL] [Abstract][Full Text] [Related]
35. A pharmacokinetic and pharmacodynamic study of the potential drug interaction between tasosartan and atenolol in patients with stage 1 and 2 essential hypertension.
Andrawis NS; Battle MM; Klamerus KJ; Burghart PH; Neefe L; Weinryb I; Mayer P; Abernethy DR
J Clin Pharmacol; 2000 Mar; 40(3):231-41. PubMed ID: 10709151
[TBL] [Abstract][Full Text] [Related]
36. Modeling of the pharmacokinetic/pharmacodynamic interaction between irbesartan and hydrochlorothiazide in normotensive subjects.
Hedaya MA; Helmy SA
Biopharm Drug Dispos; 2015 May; 36(4):216-31. PubMed ID: 25545238
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers.
Iqbal M; Khuroo A; Batolar LS; Tandon M; Monif T; Sharma PL
Clin Ther; 2010 Mar; 32(3):588-96. PubMed ID: 20399995
[TBL] [Abstract][Full Text] [Related]
38. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers.
Luzier AB; Killian A; Wilton JH; Wilson MF; Forrest A; Kazierad DJ
Clin Pharmacol Ther; 1999 Dec; 66(6):594-601. PubMed ID: 10613615
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic interaction between pitavastatin and valsartan: a randomized, open-labeled crossover study in healthy male Korean volunteers.
Jung JA; Noh YH; Jin S; Kim MJ; Kim YH; Jung JA; Lim HS; Bae KS
Clin Ther; 2012 Apr; 34(4):958-65. PubMed ID: 22410289
[TBL] [Abstract][Full Text] [Related]
40. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers.
Goldberg MR; Tanaka W; Barchowsky A; Bradstreet TE; McCrea J; Lo MW; McWilliams EJ; Bjornsson TD
Hypertension; 1993 May; 21(5):704-13. PubMed ID: 8491505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
